Results 231 to 240 of about 34,512 (245)

Unveiling the Mysteries of Molecular Testing in AML: A Guide for Oncologists [Podcast]. [PDF]

Blood Lymphat Cancer
Zeidan AM, Loghavi S.
europepmc   +1 more source

Feasible and Rapid Screening of <i>IDH1/2</i> and <i>FLT3-TKD2</i> Mutations by High-Resolution Melting for Patients with Acute Myeloid Leukemia. [PDF]

Diagnostics (Basel)
Gil JV, de Las Heras S, Miralles A, Sargas C, Llop M, Rodríguez-Veiga R, Torres-Miñana L, Boluda B, Cano-Ferri I, Acuña-Cruz E, Navarro I, Lloret-Madrid P, Montesinos P, Barragán E.   +13 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Abstract 4620: Wild-type IDH1: A molecular target in IDH1 mutant cancers

Cancer Research, 2014
Abstract Neomorphic mutations targeting R132 of the TCA cycle enzyme, IDH1, have been identified in multiple cancer types and lead to a build up of (R)-2-hydroxyglutarate ((R)-2HG). Several mechanisms have been proposed to account for mutant-IDH1-mediated transformation: due to its structure similarity with alpha-ketoglutarate (α-KG), (R)
Paul Russell, Tom Henley, Jonathan D. Moore, Christine Schofield, Julie A Wickenden, Mark Stockdale, Dan Gitterman, Jane Elliott, Chris Torrance, Amy Smith   +9 more
openaire   +2 more sources

IDH1/2 mutation detection in gliomas

Brain Tumor Pathology, 2014
Somatic mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) are strongly associated with pathological subtypes, genetic profiles, and clinical features in gliomas. The IDH1/2 status is currently regarded as one of the most important molecular markers in gliomas and should be assessed accurately and robustly.
Naoya Hashimoto, Hideyuki Arita, Yoshitaka Narita, Akihiko Yoshida, Toshiki Yoshimine, Koichi Ichimura   +5 more
openaire   +3 more sources

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor

European Journal of Medicinal Chemistry, 2023
Through a structure-based irreversible drug design approach, we have discovered a highly potent IDH1-mutant inhibitor compound 16 (IHMT-IDH1-053) (IC50 = 4.7 nM), which displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants.
Qianmao Liang, Beilei Wang, Fengming Zou, Gongrui Guo, Wenliang Wang, Wei Wang, Qingwang Liu, Lijuan Shen, Chen Hu, Wenchao Wang, Aoli Wang, Tao Huang, Yuying He, Ruixiang Xia, Jian Ge, Jing Liu, Qingsong Liu   +16 more
openaire   +2 more sources

IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis

Virchows Archiv, 2019
Mosaic somatic mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) genes have been identified in most enchondromas by targeted mutation analysis. Next-generation sequencing (NGS), that may detect even low-level mosaic mutation rates, has not previously been applied to enchondromas.
Saiji, Essia, Gumy Pause, Fabienne, Lascombes, Pierre François Marie, Cerato, Christelle, Marq-Lin, Nathalie, Berczy, Margaret, Merlini, Laura, Rougemont-Pidoux, Anne-Laure   +7 more
openaire   +4 more sources

Targeting IDH1/IDH2 mutations in gliomas

Current Opinion in Neurology, 2022
Purpose of review Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2–3 diffuse glioma and the most powerful positive prognostic factor for survival in gliomas. The purpose is to review experimental therapeutic approaches targeting IDH mutations in
openaire   +2 more sources

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo

Acta Neuropathologica, 2017
Mutations in codon 132 of isocitrate dehydrogenase (IDH) 1 are frequent in diffuse glioma, acute myeloid leukemia, chondrosarcoma and intrahepatic cholangiocarcinoma. These mutations result in a neomorphic enzyme specificity which leads to a dramatic increase of intracellular D-2-hydroxyglutarate (2-HG) in tumor cells. Therefore, mutant IDH1 protein is
Christel Herold-Mende, Ann Christin Beck, Viktoria Eichwald, Stefan Kaulfuss, Luisella Toschi, Andrea Haegebart, Holger Hess-Stumpp, Jessica Eisel, Michael Platten, Michael Platten, Manfred Jugold, Hartmut Rehwinkel, Sonja Krausert, Andreas Unterberg, Judith Guenther, Wolfgang Wick, Wolfgang Wick, Stefan Pusch, Stefan Pusch, Roman C. Hillig, Jörg Balss, Jörg Balss, Daniel Schrimpf, Daniel Schrimpf, Martina Ott, Martina Ott, Markus Bauser, Roland Neuhaus, Felix Sahm, Felix Sahm, Andreas von Deimling, Andreas von Deimling, Katja Zimmermann, Viktoria Fischer, Viktoria Fischer, David Capper, David Capper, Olaf Panknin   +37 more
openaire   +3 more sources

Metabolism of glioma and IDH1/IDH2 mutations

Revue Neurologique, 2011
Many known oncogenic signaling pathways involved in gliomagenesis have strong consequences on tumor cell metabolism, and promote the switch from oxidative phosphorylation to aerobic glycolysis, for ATP generation. However, the interest on metabolism has been recently renewed by the discovery of recurrent mutation of IDH1 genes by systematic sequencing ...
Marta Rossetto, Pietro Ciccarino, Blandine Boisselier, Marianne Labussière, Marc Sanson   +4 more
openaire   +3 more sources

Ivosidenib for advanced IDH1-mutant cholangiocarcinoma

The Lancet Oncology, 2020
Lorenzo Gervaso, S. Pellicori, Nicola Fazio   +2 more
openaire   +3 more sources